Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NPM1-mutant Refractory or Relapsed AML”

2 trials

Showing 2 of 2 results

Early research (Phase 1)Looking for participantsNCT06001788
What this trial is testing

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AMLAML With Mutated NPM1Hematologic Malignancy+9 more
Kura Oncology, Inc. 171
Early research (Phase 1)Not Yet RecruitingNCT07355335
What this trial is testing

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Who this might be right for
KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
Massachusetts General Hospital 24

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation